phase-2b

The Oral GLP-1 Race Just Got a Third Serious Contender, and Its Curve Was Still Climbing

Structure Therapeutics' once-daily oral GLP-1 aleniglipron hit 11.3 percent placebo-adjusted weight loss at 36 weeks and kept climbing in the open label. The catch: oral semaglutide and orforglipron already cleared the FDA.